CDK9 and acute myeloid leukemia: PF15 also degraded ITD-D835V and ITD-F691L mutations and was validated by xenograft model.291 Concurrently, Soural et al. designed a novel dual FLT3/CDK9-targeting PROTAC, based on the purine inhibitor BPA311, showing significant selectivity and efficacy comparable to its parent inhibitor in AML cells with FLT3-ITD mutations, although direct comparisons with FLT3 or CDK9 degraders were not conducted.292